Immuneering uses advanced proprietary techniques to identify hidden signals and biological insights across an array of genetic, genomic and proteomic data that can direct research for improved discovery, development and clinical success.
Over the past several years, the two firms have been jointly working to unlock significant findings into genetic biomarkers, therapy-specific gene expression signatures and breakthrough work in characterizing non-biological complex drugs (NBCDs).
Teva Global R&D president and chief scientific officer Michael Hayden said: "Immuneering brings together state-of-the-art analytics know-how with expertise in integrating multiple biologically- and clinically-relevant inputs.
"Their ability to cut through, link and interpret enormous and disparate data-sets is outstanding. This capability is invaluable in capturing difficult-to-find signals, confirming them in follow-up experiments, and informing decision-making that de-risks and optimizes development of therapeutic approaches.
"Simply put, by intensifying the relationship between Teva’s team, led by Dr. Iris Grossman, and the MIT-trained Immuneering team, we will be closer to helping match the right patient to the right medicine at the right time."
Under the deal, Teva secures exclusive rights to Immuneering’s analytics platforms developed to advance research and treatments for diseases of the central nervous system (CNS).